Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment

Diabetic Medicine

Volumn 24, Issue 1, 2007, Pages 94-97

  Shetty, C ^a   Balasubramani, M ^a   Capps, N ^b   Milles, J ^a   Ramachandran, S ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

High density lipoprotein cholesterol; Paradox; Pioglitazone; Rosiglitazone

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; ROSUVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SIGNAL TRANSDUCTION;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; ENGLAND; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 33846210119     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02029.x     Document Type: Article

References (17)

1. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). Br Med J 1998; 316: 823-828.
2. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
3. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-396.
4. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-2104.
5. Collinson PO, Hjelm CJ, Canepo-Anson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 1996; 33: 159-161.
6. Crook M, Lynas J, Wray R. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors. J Clin Pathol 2002; 55: 976.
7. Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem 1999; 36: 523-525.
8. Ebcioglu Z, Morgan J, Carey C, Capuzzi D. Paradoxical lowering of high-density lipoprotein cholesterol level in two patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med 2003; 139: W80.
9. Normen L, Frohlich J, Montaner J, Harris M, Elliott T, Bondy G. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004; 27: 2241-2242.
10. Sarker A, Semple RK, Dinneen SF, O'Rahilly S, Martin SC. Severe hypo-α-lipoproteinemia during treatment with rosiglitazone. Diabetes Care 2004; 27: 2577-2580.
11. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
12. Goldstein BJ. Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metab Res Rev 2002; 18: S16-22.
13. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-952.
14. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7: 162-169.
15. Gegick CG, Altheimer MD. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Curr Med Res Opin 2004; 20: 919-930.
16. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
17. World Health Organization. WHO Drug Information Bulletin. 2005; 19: 208.